Neurotech International Ltd: NTI164 Reverses Immune Dysregulation in PANDAS/PANS Children
Neurotech International Ltd: Neurotech ESG Report
Neurotech International Ltd: US FDA orphan drug designation requested for Rett Syndrome
Neurotech International Ltd: Appendix 4G and Corporate Governance Statement
Neurotech International Ltd: Neurotech Global Partnering and Registration Strategy
Neurotech International Ltd: Further Significant Improvement in Rett Syndrome Patients
Neurotech International Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Neurotech International Ltd: Phase II/III autism trial shows further benefits
Neurotech International Ltd: Significant improvement in Autism patients at 12 weeks
Neurotech International Ltd: US FDA orphan drug designation requested for PANDAS/PANS
Neurotech International Ltd: Appointment of Chief Medical Officer
Neurotech International Ltd: Release of Shares from Voluntary Escrow
Neurotech International Ltd: Expert PANDAS/PANS panel established post TGA meeting
Neurotech International Ltd: Phase I/II Autism Patients Meet 2 Years of NTI164 Treatment
Neurotech International Ltd: Further clinical benefit at 52 weeks in PANDAS/PANS patients
Neurotech International Ltd: NTI Formalises Strategic Partnership with Fenix Innovation
Neurotech International Ltd: Notice of Change of Auditor
Neurotech International Ltd: Change of Director's Interest Notice
Neurotech International Ltd: Investor Webinar on Rett Syndrome Clinical Trial Results
Neurotech International Ltd: Rett Syndrome Phase I/II trial shows significant benefits
No Data